Oncology Antibody Drug Conjugates Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Oncology Antibody Drug Conjugates Market is projected to grow from USD 9.87 billion in 2022 to USD 22.48 billion at a CAGR value of 12.4% from 2022 to 2027. Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Daiichi Sankyo, AstraZeneca, Sanofi, AbbVie, Merck & Co., Byondis, RemeGen, ImmunoGen, Seagen, Rakuten Medical, BioAtla, Bicycle Therapeutics, ADC Therapeutics, Genmab, Helix BioPharma, CytomX, and Innate Pharma, among others, are the some of the key players in the oncology antibody drug conjugates market
Browse 155 Market Data Tables and 133 Figures spread through 156 Pages and in-depth TOC on “Global Oncology Antibody Drug Conjugates Market Forecast to 2027’’ https://www.globalmarketestimates.com/market-report/oncology-antibody-drug-conjugates-market-3781
By Indication (Breast Cancer, Ovarian Cancer, Cervical Cancer, NSCLC, Colorectal Cancer, Pancreatic Cancer, Hodgkin Lymphoma, Leukemia, Gastric Cancer), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis
Indication Size Outlook (Revenue, USD Billion, 2022-2027)
Breast Cancer
Ovarian Cancer
Cervical Cancer
NSCLC
Colorectal Cancer
Pancreatic Cancer
Hodgkin Lymphoma
Leukemia
Gastric Cancer
Others
Regional Outlook (Revenue, USD Billion, 2022-2027) North America
The U.S. Canada Mexico
Europe
Germany UK France Spain Italy Rest of Europe
Asia Pacific
China India Japan South Korea Australia Rest of APAC
Central & South America
Brazil Argentina Rest of CSA
Middle East & Africa
Saudi Arabia UAE Rest of MEA
Contact: Yash Jain Email address: yash.jain@globalmarketestimates.com Phone Number: +1 6026667238